Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
107 participants
INTERVENTIONAL
2015-04-30
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
No preoperative phenazopyridine
No interventions assigned to this group
Phenazopyridine
Preoperative phenazopyridine
Phenazopyridine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Phenazopyridine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Planned surgical procedure where cystoscopy will be used to document ureteral urine flow
* Age \> or = 18 years, no upper age limit
* Able and willing to consent
Exclusion Criteria
* Planned surgical procedure where cystoscopy is used for a purpose other than documenting ureteral urine flow
* age \<18 years
* pregnancy
* unable/unwilling to participate
* history of allergy or adverse reaction to phenazopyridine
* hepatic dysfunction
* known phenazopyridine hypersensitivity
* history of urologic surgery
* presence of ureteral stents prior to the planned surgical procedure
* concomitant suprapubic catheter placement
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hartford Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Katie Propst
Fellow
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hartford Hospital
Hartford, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Propst K, Tunitsky-Bitton E, O'Sullivan DM, Steinberg AC, LaSala C. Phenazopyridine for Evaluation of Ureteral Patency: A Randomized Controlled Trial. Obstet Gynecol. 2016 Aug;128(2):348-355. doi: 10.1097/AOG.0000000000001472.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HHC-2015-0008
Identifier Type: -
Identifier Source: org_study_id